Prof. KP schreef op 15 november 2024 12:24:
Nog even de link naar het document toegevoegd.
Slecht nieuws voor Pharming betreffende vergoeding in de UK !
UK NICE does NOT recommend leniolisibRecommendations
1.1 Leniolisib is not recommended, within its marketing authorisation, for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.
There are uncertainties in the economic modelling around how best to model the effect of stopping treatment.
...
Because of the uncertainties in the economic model, it is not possible to determine the most likely cost-effectiveness estimates for leniolisib. So it is not recommended
Volledig document op NICE website
www.nice.org.uk/guidance/GID-HST10059...Dit kan in Europa ook nog wel eens voor problemen gaan zorgen.